A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to produce protective antibodies, which are then passed to the foetus through the placenta. This mother-derived protection offers newborns with instant defence from the point of delivery, exactly when they are most vulnerable to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence indicating that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85% coverage when vaccinated four weeks before birth
- Maternal antibodies transferred through the placenta protect newborns from day one
- Protection achievable with 2-week gap before early delivery
- Vaccination during third trimester still offers significant infant protection
Compelling evidence from recent research
The efficacy of the pregnancy RSV vaccine has been confirmed through a thorough investigation carried out throughout England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month timeframe, providing comprehensive and reliable evidence of the vaccine’s real-world impact. The study’s findings have been endorsed by the UK Health Security Agency as showing robust protection for newborns during their most vulnerable early months. The scope of this study provides healthcare professionals and expectant parents with trust in the vaccine’s established performance across diverse populations and circumstances.
The results reveal a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This marked difference highlights the vaccine’s critical role in protecting against serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Study methodology and scope
The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection rates and hospital admissions. The substantial sample size and thorough nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology captured real-world outcomes rather than laboratory-based settings, providing real-world data of how the vaccine performs when given across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the dangers
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection triggers inflammation deep within the lungs and airways, making it perilously hard for vulnerable newborns to feed and breathe properly. Parents commonly see their babies struggling visibly, their chests rising whilst they attempt to draw sufficient oxygen into their compromised lungs. Whilst most infants improve through supportive care, a limited though important proportion perish from RSV-related complications annually, making vaccination as prevention a essential public health priority for protecting the most vulnerable and youngest people in our communities.
- RSV triggers inflammation in lungs, causing serious respiratory problems in babies
- Half of all infants acquire the infection during their first few months alive
- Symptoms span from mild colds to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- A small number of babies succumb to RSV complications each year in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the importance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing is crucial for ensuring newborns benefit from the strongest possible immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts encourage women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to maximise the antibodies transferred to their babies via the placenta.
The guidance from health authorities stays clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to pregnant women that protection is still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This flexible approach recognises the realities of pregnancy and childbirth whilst ensuring strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of serious illness.
Regional variations in immunisation
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Some areas have achieved higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to boost understanding and availability of the jab. These geographical variations reflect variations in medical facilities, engagement approaches, and local engagement efforts, though the national data shows robust and reliable protection irrespective of geographical location.
- NHS trusts launching multiple messaging strategies to connect with women during pregnancy
- Regional disparities in vaccination coverage levels across England require targeted improvement
- Local healthcare systems adapting programmes to meet local requirements and situations
Real-world impact and parent viewpoints
The vaccine’s remarkable effectiveness delivers real advantages for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the introduction of this safeguarding intervention, the 80% decrease in admissions means thousands of infants spared from critical disease. Parents no longer face the upsetting situation of watching their newborns struggle for breath or struggle to eat, symptoms that characterise critical RSV illness. The vaccine has substantially transformed the picture of neonatal breathing health, offering expectant mothers a proactive tool to shield their most at-risk babies during those critical early months.
For families like that of Malachi, whose severe RSV infection resulted in profound brain damage, the vaccine’s availability carries profound emotional significance. His mother’s support of the jab highlights the profound consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to expectant mothers navigating their late pregnancy, transforming what was once an inevitable seasonal threat into a manageable health risk.